Nov 30,2020

Qure X-ray solution launched on Blackford Platform

Blackford, the platform for medical imaging applications and AI, today announced that Qure.ai’s qXR solution is now available on Blackford Platform. qXR is an AI-powered solution that reads and triages chest X-rays, reducing the chances of late diagnoses, under diagnoses and even potential misdiagnoses to deliver better patient care. Using deep learning algorithms to read and triage chest X-rays in less than a minute, qXR detects abnormal findings. Its patented algorithms can detect a total of 29 findings in a chest X-ray, including detection of multiple findings in the lungs, pleura, heart, bones and diaphragm.

COLLABORATION PARTNERSHIP

#connected device

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Aug 01,2021

Qlarity Imaging and Blackford Partner to Bring QuantX™ Diagnostic AI to More Breast Radiologists via Blackford Platform™, helping more patients in need

 Qlarity Imaging, a leading innovator in artificial intelligence (AI) diagnostics and portfolio company of Paragon Biosciences, and Blackford, the provider of the dedicated platform for medical imaging applications and AI, today announced their agreement to integrate QuantX™ within Blackford’s curated marketplace. The partnership will combine the implementation and maintenance gains of a platform-based approach with the increased accuracy and improved reader performance benefits of QuantX™ for breast MRI interpretation to help deliver better outcomes for more radiologists, health systems, and most importantly patients. The integration will feature the new cloud-based, vendor neutral format of QuantX™, which is currently in development and pending application seeking FDA clearance.

COLLABORATION PARTNERSHIP

#connected device

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Nov 23,2021

Aidence lung nodule AI tool launched on Blackford Platform

Blackford, the platform for medical imaging applications and AI, today announced that the Veye Lung Nodules tool is now available on Blackford Platform. Developed by Aidence, Veye Lung Nodules is an AI-based solution for pulmonary nodule management on chest CT scans. The tool detects, measures, classifies, and tracks the growth of pulmonary nodules as small as 3 mm. The solution is CE-marked as a class IIb medical device under the new EU Medical Device Regulation and can be used as a second or concurrent reader. Blackford’s single dedicated platform transforms the deployment, orchestration, management and support of multiple imaging applications and AI tools. 

COLLABORATION PARTNERSHIP

#connected device

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Jan 18,2023

Blackford announces its acquisition by Bayer

Blackford Analysis is proud and delighted to announce Blackford’s acquisition by Bayer, the global life science company. Following the acquisition, Blackford will continue to operate independently based on Bayer’s well-established ‘arm’s length’ operating model. The company will remain accountable to advance its technology, channel partnerships and clinical application portfolio while benefiting from the experience, infrastructure and reach of Bayer as a global pharmaceutical company. 

COLLABORATION MERGERS & ACQUISITION

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 04,2018

OWise receives top prize in Scotland’s Cancer Innovation Challenge

OWise received a £100,000 award to progress to the second phase of Scotland’s prestigious Cancer Innovation Challenge. It was one of the projects selected to progress to phase two of the Cancer Innovation Challenge, which aimed to inspire novel data and tech innovations to help Scotland become a world leader in cancer care.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Mar 10,2020

OWise wins top NESTA Healthier Lives Data Fund Prize

Px Healthcare won £60,000 in funding from the Scottish Government to keep developing their products and scale them across Scotland. This funding was in addition to the £30,000 originally awarded to organisations involved in the Healthier Lives Data Fund. This fund is a partnership between Nesta and the Scottish Government which, over the last year, has supported six projects in Scotland that demonstrated what can be achieved when health or care data is used to give control back to the individual.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Jun 30,2017

Owise Receives CE Mark Class I Medical Device Status

OWise was CE-marked to comply with the European regulatory standards for safety and usage on the 7th of May, 2014. “It is for us of prime importance that patients are well supported throughout their treatment, which is why we wanted to make sure that OWise is safe to use and fit for purpose.” – said Dr. Anne Bruinvels, founder of OWise.

REGULATORY CE MARK

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 01,2018

Owise from Px Healthcare Enters NHS Library

OWise is one in five cancer apps listed in the NHS app library. OWise has met standards sourced by NHS (DTAC), including evidence of clinical safety, privacy (GDPR 2018), security, usability, accessibility and technical stability.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 08,2014

Mayo Clinic and IBM Task Watson to Improve Clinical Trial Research

Mayo Clinic and IBM today announced plans to pilot Watson, the IBM cognitive computer, to match patients more quickly with appropriate clinical trials, beginning with research studies in cancer. A proof-of-concept phase is currently underway. This version of Watson will be especially designed for Mayo Clinic. As it progresses in its tasks and matures through this collaboration, it will learn more about the clinical trials matching process, become even more efficient and likely more generalizable.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 31,2018

Elekta and IBM Watson Health Bringing Artificial Intelligence to Oncology

Elekta announced it is collaborating with IBM Watson Health to offer Watson for Oncology with Elekta’s cancer care solutions. Under the terms of a new agreement, Elekta will sell Watson for Oncology beginning in early 2018 as a clinical decision support solution paired within Elekta’s digital cancer care solutions, including the Mosaiq oncology information system. Elekta intends to offer both solutions in most markets around the world including the U.S., Brazil, certain major European and Asian markets, as well as India and Australia.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY